HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Citarinostat

HCID 53340426
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1316215-12-9
Standard SMILES
O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1)NO
InChIKey
VLIUIBXPEDFJRF-UHFFFAOYSA-N
Molecular formula
C24H26ClN5O3
Average molar mass
467.9 g/mol
Monoisotopic mass
467.1724174

Overview

Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).

Names & identifiers

Preferred name
Citarinostat
IUPAC
2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
English name
Citarinostat
Molecular formula
C24H26ClN5O3
Molecular weight
467.95

Names & synonyms

Citarinostat1316215-12-9ACY-241HDAC-IN-22-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamideACY241441P620G3P2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-Pyrimidinecarboxamide, 2-((2-chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-7-({2-[(2-chlorophenyl)(phenyl)amino]pyrimidin-5-yl}formamido)-N-hydroxyheptanamide
Show more names
CS-1760ACY-241(CITARINOSTAT)Citarinostat (ACY-241)Citarinostat, 10 mM in DMSOCitarinostat (ACY-241) ,S8464Citarinostat(ACY-241,HDAC-IN-2)ACY 241CITARINOSTAT.
citarinostatum2-(N-(2-chlorophenyl)anilino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide7-((2-((2-chlorophenyl)(phenyl)amino)pyrimidin-5-yl)formamido)-N-hydroxyheptanamideRefChem:126503Histone Deacetylase Inhibitor ACY-241CC-962412-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamideMFCD28023593

Properties

Computed structural propertiesFilling in

XLogP
4.1
Topological polar surface area
107 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
6
Rotatable bonds
11
Heavy atoms
33
Formal charge
0
Complexity
597

Physicochemical properties

Density
1.293 · 1.293±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
solubility
23.4 mg/mL · ≥23.4 mg/mL in DMSO; insoluble in H2O; ≥4.87 mg/mL in EtOH with ultrasonic
form
solid
pka
9.47 · 9.47±0.20(Predicted)
color
White to off-white
FDA UNII
441 P620G3P · 441P620G3P
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501

Chemistry & industry

Pharmacology

MeSH Pharmacological ClassificationCompounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
Applications · 2 items

DescriptionACY-241 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 2.6 nM). It is selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all). It reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells when used at a concentration of 3 μM and completely inhibits it and induces apoptosis at a concentration of 10 μM. ACY-241, when used in combination with paclitaxel , inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells. It also reduces tumor growth in a MiaPaCa-2 mouse xenograft model when administered at a dose of 50 mg/kg in combination with paclitaxel. ACY-241, in combination with the somatostatin receptor agonist pasireotide , reduces hepatorenal cystogenesis in a rat model of polycystic liver disease.

UsesCitarinostat is a HDAC inhibitor.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
1316215-12-9
PubChem CID
53340426
ChEMBL
CHEMBL3693786
UNII
441P620G3P